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Abstract
Background: CDCP1, a transmembrane protein with tumor pro-metastatic activity, was recently identified as a
prognostic marker in TNBC, the most aggressive breast cancer subtype still lacking an effective molecular targeted
therapy. The mechanisms driving CDCP1 over-expression are not fully understood, although several stimuli derived from
tumor microenvironment, such as factors present in Wound Healing Fluids (WHFs), reportedly increase CDCP1 levels.
Methods: The expression of CDCP1, PDGFRβ and ERK1/2cell was tested by Western blot after stimulation of MDA-MB-
231 cells with PDGF-BB and, similarly, in presence or not of ERK1/2 inhibitor in a panel of TNBC cell lines. Knock-down of
PDGFRβ was established in MDA-MB-231 cells to detect CDCP1 upon WHF treatment. Immunohistochemical staining was
used to detect the expression of CDCP1 and PDGFRβ in TNBC clinical samples.
Results: We discovered that PDGF-BB-mediated activation of PDGFRβ increases CDCP1 protein expression through the
downstream activation of ERK1/2. Inhibition of ERK1/2 activity reduced per se CDCP1 expression, evidence strengthening
its role in CDCP1 expression regulation. Knock-down of PDGFRβ in TNBC cells impaired CDCP1 increase induced by WHF
treatment, highlighting the role if this receptor as a central player of the WHF-mediated CDCP1 induction. A significant
association between CDCP1 and PDGFRβ immunohistochemical staining was observed in TNBC specimens,
independently of CDCP1 gene gain, thus corroborating the relevance of the PDGF-BB/PDGFRβ axis in the modulation of
CDCP1 expression.
Conclusion: We have identified PDGF-BB/PDGFRβ–mediated pathway as a novel player in the regulation of CDCP1 in
TNCBs through ERK1/2 activation. Our results provide the basis for the potential use of PDGFRβ and ERK1/2 inhibitors in
targeting the aggressive features of CDCP1-positive TNBCs.
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Background
Triple-negative breast cancers (TNBCs) comprise mam-
mary carcinomas that do not express estrogen receptors
(ERs), progesterone receptors (PRs), and human epider-
mal growth factor receptor-2 (HER-2). TNBCs are an
aggressive tumor subtype, characterized by a high risk of
recurrence within 5 years after diagnosis and a high
mortality rate [1, 2]. Due to the lack of specific molecu-
lar targets, chemotherapy remains the standard systemic
therapy for TNBCs, but it has dissatisfactory long-term
results. Recently, we proposed the transmembrane pro-
tein CUB domain-containing protein-1 (CDCP1), which
is overexpressed in TNBCs and involved in tumor pro-
gression, as a new therapeutic target for TNBCs [3].
CDCP1 is a cleavable transmembrane protein that is
overexpressed in several types of cancer cells [4–10].
CDCP1 encodes a 135-kDa protein that is proteolyzed
into a cleaved 70-kDa form [11–13], which can homodi-
merize and initiate prometastatic activity [11, 14].
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CDCP1 increases the migration and invasiveness of
cancer cells and anchorage-independent cell survival
[15, 16] through its interaction with important sig-
nalling pathways in tumor aggressiveness, such as
Akt [11], PKCδ [17], Src [12, 14, 16, 18–20], and
Extracellular signal-regulated kinases 1–2 (ERK1/2)
[21]. Accordingly, several studies have suggested that
the overexpression of this protein in tumors is re-
lated to worse outcomes in lung cancer [4], pancre-
atic cancer [5], renal cell carcinoma [7], ovarian
cancer [8], and hepatocellular carcinoma [9]. The
mechanisms by which CDCP1 expression is regu-
lated in TNBCs are unknown.
The correlation that we observed between a gain in
CDCP1 copy number and the number of cells that express
CDCP1 in TNBCs supports that CDCP1 polysomy is in-
volved in CDCP1 overexpression in this breast cancer sub-
type. However, because approximately 50% of TNBC
tumors overexpressing CDCP1 lack polysomy, the CDCP1
expression might be regulated by transcriptional and
post-translational mechanisms, regardless of a genetic gain
(e.g., by influencing the half-life of CDCP1 through
EGFR-mediated inhibition of palmitoylation-dependent
degradation of CDCP1 [22]). We demonstrate that activa-
tion of platelet-derived growth factor receptors beta
(PDGFRβ) by PDGF-BB upregulates CDCP1 expression
and that ERK1/2 activation is crucial for this upmodulation.
Consistently, a significant association between CDCP1 and
PDGFRβ expression was observed in TNBC specimens, in-
dependent of gains in CDCP1, confirming the link between
these two molecules.
Methods
Cell lines, cultures, and treatments
The human breast cancer cell lines MDA-MB-231
(ATCC® HTB-26™), BT549 (ATCC® HTB122™),
HCC1937 (ATCC® CRL 2336™), MDA-MB-468 (ATCC ®
HTB-132™), (American Type Culture Collection,
Manassas, VA), SUM149, and SUM159 (Asterand Bio-
science, Detroit, MI now acquired by Bioreclamatio-
nIVT, Westbury, NY) were authenticated using a panel
of microsatellite markers. Cell lines were maintained at
37 °C in a humidified atmosphere of 5% CO2 as previ-
ously described in Turdo et al. [3]. For stimulation ex-
periments, MDA-MB-231 cells were starved in
serum-free medium for 24 h and then treated for 48 h
with a pool of 5 WHFs at a final concentration of 5% as
described [23] or with PDGF-BB, Mib1b, MCP1, IP10,
Il1ra, Il1b, G-CSF, Il8, Il6, EGF, FGF, Heregulin,
PDGF-AA, PDGF-AB (PeproTech, Rocky Hill, NJ) at
50 ng/mL. Cells were treated in indicated experiments
with cycloheximide (1 μM) or UO126 (2 μM), both of
which were dissolved in DMSO (maximum concentra-
tion 0.1%) (Sigma-Aldrich).
Antibodies
FACS analysis was performed with Alexa Fluor® 647
anti-human CD318 (CDCP1) (BioLegend, San Diego,
CA). Biochemical analyses were performed using rabbit
polyclonal antibodies against CDCP1, phospho-CDCP1
(Tyr734), p44/42 MAPK (ERK1/2), phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling, Dan-
vers, MA), and PDGFRβ (Santa Cruz Biotechnology, Dal-
las, TX) or mouse monoclonal anti-phospho-PDGFRβ
(Tyr751) (clone 88H8) (Cell Signaling); polyclonal
anti-rabbit or -mouse IgG (GE Healthcare, Chicago, IL)
was the secondary antibody. Actin was revealed by prob-
ing with peroxidase-linked mouse monoclonal anti-actin
(Sigma-Aldrich).
Western blot
To prepare crude cell lysates, cells were processed as de-
scribed [24]. Protein concentrations were determined by
Coomassie Plus protein assay (Thermo Fisher Scientific,
Waltham, MA). The samples were separated on NuPage
SDS-Bis-Tris gels (Thermo Fisher Scientific) and trans-
ferred to PVDF membranes (Merck Millipore, Billerica,
MA). Signals were detected using ECL reagent (GE
Healthcare). Protein expression was normalized to that
of actin, and densitometry was performed in Quantity
One 4.6.6 (Bio-Rad, Hercules, CA).
Cytofluorimetric analysis
CDCP1 protein was detected by FACScan analysis by
staining cells with PE anti-human CD318 (CDCP1) Anti-
body (BioLegends). Cells not stained with antibody were
used as controls. The gates were set based on light scatter
properties after debris and doublet exclusion; a represen-
tative gating strategy is shown in Additional file 1: Figure
S1. Samples were analyzed using a FACSCalibur flow cyt-
ometer (BD Bioscineces) and FlowJo software (TreeStar).
Knockdown of PDGFRβ by siRNA transfection
To knock down PDGFRβ, cells were transfected with
100 nM of specific silencer siRNA (ID s10242) or a N.1
negative control siRNA (Thermo Fisher Scientific) using
RNAiMAX (Life Technologies), harvested at 48 h
post-transfection, and examined for protein expression by
western blot.
Patients
Samples from 65 TNBC patients diagnosed between Au-
gust 2002 and February 2007 were collected in our institute
(Fondazione IRCCS Istituto Nazionale dei Tumori) [3, 25].
Immunohistochemistry
Expression of CDCP1 and PDGFRβ was analyzed by IHC
in consecutive 2-μm formalin-fixed, paraffin-embedded
(FFPE) tumor sections, using rabbit polyclonal anti-CDCP1
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(1:50) (PA5–17245, Thermo Fisher Scientific) and rabbit
anti-human PDGFRβ (1:200) (Y92, Abcam), respectively.
Antigen retrieval was performed by heating the sections for
5 min at 96 °C in 10 mM citrate buffer, pH 6.0. Staining
was visualized using streptavidin-biotin-peroxidase (Dako,
Agilent Technology, Santa Clara, CA) and 3,3′-diamino-
benzidine (DAB; brown signal) (Dako), and the sections
were counterstained with hematoxylin. Images were ac-
quired by ECLIPSE TE2000-S inverted microscope (Nikon
Instruments, Melville, NY) at 20X and 40X magnification.
The reactivity of anti-CDCP1 and anti-PDGFRβ was con-
sidered to be positive per Turdo 2016 and D’Ippolito 2016
[3, 25]. Specifically, based on the intensity of PDGFRβ
staining in neoplastic cells, we assigned tumors a score of 0
(absence of signal) or 1 (weak to strong cytoplasmic signal
and membrane signal). Reactivity of polyclonal anti-CDCP1
was defined as positive when ≥10% of tumor cells showed
membrane staining.
Fluorescence in situ hybridization (FISH)
All FISH analyses were performed in FFPE tissues in
areas that were selected by the pathologist as being
CDCP1-positive by IHC or, for IHC-negative cases, rep-
resentative of the tumor. Tumors were classified as posi-
tive or negative per Turdo et al. [3].
Statistical analysis
Relationships between categorical variables were ana-
lyzed by Fisher’s exact test. Differences were considered
to be significant at p ≤ 0.05. All analyses were performed
using SAS 9.4 (SAS Institute Inc.).
Results
PDGFRβ regulates CDCP1 expression in TNBC cells
To examine the molecules that regulate CDCP1 expres-
sion in TNBCs, the TNBC cell line MDA-MB-231 was
stimulated for 48 h with various ligands, including
growth factors, cytokines, and chemokines in wound
healing fluids (WHFs) [26], that we found upregulate
CDCP1 robustly [3]. This panel of molecules was chosen
from small molecules that are involved in breast cancer
progression. Plasma membrane CDCP1 levels were de-
termined by cytofluorimetry, and the percentage of in-
crease in expression following stimulation with each
molecule was calculated respect to the maximum in-
crease that was induced by WHF, used as a positive
control.
Regarding growth factors, PDGF-BB was among the
strongest inducers of CDCP1 in MDA-MB-231 cells
(Fig. 1a). CDCP1 upregulation was also affected by EGF,
FGF-basic, and HRG. Of the cytokines and chemokines,
except for slight upregulation by MCP1, IL1RA, and
IL-1b, none increased CDCP1 levels, suggesting that the
regulation of CDCP1 in TNBC cells depends primarily
on growth factors. Thus, we focused on the PDGF-BB/
PDGFRβ pathway.
By western blot, we confirmed the robust upmodula-
tion of CDCP1 after PDGF-BB stimulation in
MDA-MB-231 cells (Fig. 1b). PDGF-BB-induced signal-
ling was initiated by activation of its cognate receptor,
PDGFRβ, which results still phosphorylated after 48 h of
treatment with PDGF-BB. Consistent with its stimula-
tion, the total level of PDGFRβ decreased compared with
unstimulated cells, presumably due to its postactivation
protein degradation [27]. Similarly, CDCP1 phosphoryl-
ation (Y734) rose after PDGF-BB treatment.
To confirm that the upregulation of CDCP1 protein
on PDGF-BB stimulation was attributed to greater
CDCP1 translation, MDA-MB-231 cells were stimulated
with or without the protein neosynthesis inhibitor cyclo-
heximide (CHX). By western blot, no PDGF-BB-induced
CDCP1 upmodulation occurred in the presence of CHX,
indicating that during PDGF-BB stimulation, the in-
crease in CDCP1 protein is due to protein neosynthesis
(Fig. 1c).
To verify the function of PDGFRβ in the regulation of
CDCP1 expression, PDGFRβ was transiently knocked
down in MDA-MB-231 cells for 24 h (Fig. 2a). By west-
ern blot, CDCP1 declined in PDGFRβ siRNA-treated
versus scramble siRNA-treated cells.
To determine whether PDGF-BB participates in the in-
crease in CDCP1 expression after TNBC cell stimulation
with WHFs, PDGFRβ was transiently knocked down in
MDA-MB-231 cells, which were then stimulated with
WHFs for 24 h, 24 h after siRNA transfection (Fig. 2b).
In knockdown cells, the increase of CDCP1 was partially
impaired on WHF treatment.
PDGFRβ activation triggers several transduction sig-
nals, such as the Ras-ERK pathway. ERK1/2 governs the
upregulation in CDCP1 following stimulation with
growth factors. Notably, ERK was less active in cells in
which PDGFRβ was knocked down (Fig. 2b).
PDGF-BB-induced CDCP1 upregulation depends on the
PDGFRβ/ERK axis
To determine whether ERK activation is crucial in
PDGF-BB-induced CDCP1 in our cell model, ERK status
was examined on short-term stimulation, wherein down-
stream pathways of RTK are usually activated.
MDA-MB-231 cells were starved and then treated with
PDGF-BB for 10 and 60 min, confirming that
PDGF-BB-induced PDGFRβ activation stimulated ERK1/2,
starting from 10 min and persisting at 1 h (Fig. 3a).
To confirm that PDGF-BB stimulation induces CDCP1
expression through ERK1/2 activation, MDA-MB-231
cells were treated for 24 h with PDGF-BB with or without
the ERK1/2 inhibitor UO126 (2 μM). ERK1/2 inactivation,
on PDGF-BB treatment, mitigated the upregulation of
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CDCP1. CDCP1 levels fell in the presence of UO126
(Fig. 3b). Notably, UO126 diminished basal CDCP1 levels
in unstimulated starved cells. CDCP1 upregulation upon
the activation of the PDGFRβ/ERK axis was confirmed in
two additionally triple negative breast cancer cell lines
BT-549 and SUM149 (Additional file 2: Figure S2). These
data indicate that PDGF-BB mediates the increase in
CDCP1 through the ERK1/2 pathway.
Next, we starved MDA-MB-231 cells and treated them
with or without a pool of 5 WHFs at a final concentra-
tion of 5% for 24 h, with or without UO126, to deter-
mine whether ERK1/2 activation is required for
WHF-induced upmodulation of CDCP1 in TNBCs. By
western blot, WHF increased CDCP1 levels only in the
presence of functional ERK1/2 (Fig. 3c).
To confirm that ERK1/2 is necessary for CDCP1 expres-
sion in TNBC cells, a panel of CDCP1-positive TNBC cell
lines [3] was treated with UO126 under standard culture
Fig. 2 PDGFRβ regulates CDCP1 expression in TNBC cells. aWB analysis of
PDGFRβ and CDCP1 in MDA-MB-231 cells transfected with 100 nM
PDGFRβ siRNA or the appropriate negative control. Cells were harvested at
48 h post-transfection. bWB analysis of CDCP1 and phosphoERK1/2 (T202/
Y204) in MDA-MB-231 cells transfected with 100 nM PDGFRβ siRNA or the
appropriate negative control and with or without 5% WHF in culture
medium for 24 h. Dottes lines demarcate juxtaposed images originating
from separate lines of the same western blot. The fold-change increase in
CDCP1, calculated by densitometry, was 2.3 and 1.6, respectively.
Monoclonal anti-actin was used as the total protein loading control
Fig. 1 PDGF-BB stimulation upregulates CDCP1 in TNBC cells. a CDCP1 in MDA-MB-231 cells treated with various growth factors, cytokines, and
chemokines for 48 h was analyzed by FACS and reported as percentage upregulation with respect to the maximum increase induced by WHFs
(100%). Representative experiment. b WB analysis of CDCP1, phospho-CDCP1 (Y734), PDGFRβ, and phospho-PDGFRβ (Y751) in MDA-MB-231 cells
treated with or without PDGF-BB 20 ng/ml for 48 h. The fold-change increase in phospho-CDCP1 and CDCP1, calculated by densitometry, was 1.6 and
1.9, respectively. c WB analysis of CDCP1 in MDA-MB-231 cells treated with or without PDGF-BB 20 ng/ml and/or cycloheximide (1 μM) for 24 h.
Monoclonal anti-actin was used as the total protein loading control
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conditions for 24 h (Fig. 3d). CDCP1 levels decreased in 5
of the 6 cell lines on treatment with this ERK1/2 inhibitor;
only in MDA-MB-468 cells CDCP1 expression was un-
affected by ERK1/2 inactivation. These data confirm the
implication of ERK1/2 in the regulation of CDCP1 expres-
sion in TNBCs. A schematic representation of CDCP1 up-
regulation upon PDGF-BB, PDGFRβ pathway activation,
via ERK1/2 is shown in Fig. 4.
CDCP1 and PDGFRβ expression associated in TNBC
tissues
The association between PDGFRβ and CDCP1 expression
was examined in 65 formalin-fixed, paraffin-embedded
(FFPE) primary TNBC specimens by immunohistochemis-
try (IHC) (Table 1). Of these samples, 41.5% was node
(N)-positive, and 60.0% of tumors were stage T1. As ex-
pected for TNBCs, the tumors were primarily grade III
(84.6%) and highly necrotic (75.4%). Multifocality was ob-
served in 19.9% of cases, and 35.4% of patients had ductal
carcinoma in situ (DCIS). Tumors were categorized as
CDCP1-positive or -negative per Turdo et al. [3] and were
divided according to the presence or absence of PDGFRβ
staining in association with tumor cells, as described in
D’Ippolito et al. [25] (Fig. 5).
Because we have reported the function of PDGFRβ in
mediating tumor vasculogenic properties in TNBCs [28],
and we also reported that CDCP1 knocked-down impairs
vasculogenic mimicry in vitro, TNBC tumors were then
analyzed, based on the presence or absence of PDGFRβ
staining in association with tumor cells in vascular-like
structures or organized into tumor nests. Regarding tumor
nests, 57% (37/65) of cases were CDCP1-positive, 45%
(29/65) was PDGFRβ-positive, 32% (21/65) was positive
for CDCP1 and PDGFRβ (double-positive), and 31% (20/
65) was negative for CDCP1 and PDGFRβ (double-nega-
tive). CDCP1-positive cases did not differ significantly
from their negative counterparts about clinical variables
(Table 1), but PDGFRβ positivity was significantly associ-
ated with higher grade and younger age. All cases with
grade I and II tumors did not express PDGFRβ, whereas
nearly 50% of grade III tumors were PDGFRβ-positive
(p = 0.0029; Fisher’s exact test); most PDGFRβ-positive
cases were younger than PDGFRβ-negative cases (p =
0.0040; Fisher’s exact test).
About PDGFRβ expression in tumor and vascular
lacunae according to CDCP1 levels, 72.4% (21/29) of
PDGFRβ-positive cases in tumor nests were
CDCP1-positive (Table 2; p = 0.0429; Fisher’s exact test).
In our analysis of vascular lacunae, a trend of association
was revealed between PDGFRβ in tumor cells in
vascular-like structures and CDCP1 expression (Table 2;
p = 0.0795; Fisher’s exact test).
Based on the relationship between CDCP1 expression
and gains in CDCP1, we examined whether PDGFRβ
was differentially expressed, depending on CDCP1 sta-
tus. CDCP1 status was analyzed in 53 of 65 available
TNBC specimens by fluorescence in situ hybridization
(FISH). As a result, we identified 4 genetic categories:
Fig. 3 ERK1/2 activity regulates CDCP1 expression in TNBC cells. a WB analysis of phospho-ERK1/2 (T202/Y204) in MDA-MB-231 cells treated with
or without 20 ng/ml PDGF-BB for 10 and 60 min. b WB analysis of CDCP1 and phosphoERK1/2 (T202/Y204) in MDA-MB-231 cells treated with or
without the ERK1/2 inhibitor UO126 (2 μM) and stimulated with or without 20 ng/ml PDGF-BB for 24 h. c WB analysis of CDCP1 in MDA-MB 231
cells treated with or without UO126 (2 μM) and stimulated with or without 5% WHF in culture medium for 24 h. Dotted lines demarcate
juxtaposed images originating from separate lines of the same western blot. d WB analysis of CDCP1, phosphoERK1/2 (T202/Y204), and ERK1/2 in
SUM149, SUM159, MDA-MB468, BT-549, MDA-MB-231, and HCC1937 cells treated with or without UO126 (2 μM) under standard medium
conditions for 24 h. Monoclonal anti-actin was used as the total protein loading control
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deleted (n = 2) and disomic (n = 40) cases were consid-
ered to be CDCP1-negative, and amplified (n = 2) and
polysomic (n = 9) cases were CDCP1-positive (Fig. 6).
Our FISH analysis did not reveal any imbalance in
CDCP1 gains in PDGFRβ-positive or -negative TNBC
cases (Table 3). Among FISH-positive cases, 7 of 10
CDCP1-positive cases expressed PDGFRβ; similarly,
among FISH-negative cases, 10 of 19 CDCP1-positive
cases expressed PDGFRβ (p = 0.4495). These data dem-
onstrate that CDCP1 and PDGFRβ expression is linked
in TNBC specimens, independent of gains in CDCP1.
Discussion
Our study described for the first time the role of
PDGFRβ signalling in regulating CDCP1 expression in
TNBCs. We have demonstrated that the induction of
CDCP1 peaks on treatment with PDGF-BB, among
various cytokines, chemokines, and growth factors,
highlighting its significance in the regulation of this pro-
tein in the TNBC phenotype. Notably, the increase and
maintenance of CDCP1 phosphorylation after treatment
with PDGF-BB implicate PDGFRβ in the regulation of
CDCP1 activity. Thus, we speculate that signals down-
stream of PDGFRβ are also crucial for the promotion of
CDCP1-mediated prometastatic features through the ac-
tivation of Src family kinases (SFKs). CDCP1 Tyr734 is
the primary SFK-mediated phosphorylation site [13, 29],
crucial for the recruitment of PKCδ and resulting in
CDCP1-mediated invasiveness.
Growth factor receptors that are involved in tumor pro-
gression have been implicated in CDCP1 overexpression.
The EGF-EGFR axis promotes CDCP1 expression in ovar-
ian cancer models, and bone morphogenetic protein 4 in-
duces CDCP1 in pancreatic cancer cells [5, 30]. Our
analyses suggest that growth factors other than PDGF-BB
mediate the upregulation of CDCP1. For example, HRG
(likely via EGFR/HER3 heterodimerization) and FGF
upmodulate CDCP1 on the cell membrane of TNBCs.
The redundancy of signalling pathways that are down-
stream of these tyrosine kinase receptors suggests that the
activation of several growth factor receptors converge at
common mediators in CDCP1 synthesis, the most import-
ant of which are members of the RAS/RAF/MEK/ERK
pathway, which have been implicated in CDCP1 mRNA
and protein expression. Activation of Ras-ERK signalling
alone induces CDCP1 expression in NCSLC, likely
through the transcription factor AP-1 [21].
The RAS/RAF/ERK pathway is stimulated in TNBC [31],
leading cells to acquire an aggressive phenotype—i.e., pro-
moting invasiveness and migration [32]. Thus, ERK1/2
might also promote these features through the regulation of
CDCP1 expression. Several stimuli, mediated by growth fac-
tors, converge to activate ERK1/2, paralleling the rise in
CDCP1 on the treatment of MDA-MB-231 cells with the
Fig. 4 Schematic representation of CDCP1 upregulation induced by PDGF-BB/PDGFRβ pathway through ERK1/2 activation. PDGFRβ dimerizes and is
activated upon binding of the PDGF-BB ligand, causing the activation of the kinase domain, visualized as tyrosine phosphorylation (P) of the receptor
molecules. In conjunction with dimerization and kinase activation, the receptor molecules undergoes a conformational changes, which allow a basal
kinase activity, leading to full enzymatic activity directed toward downstream mediators such as ERK1/2. ERK1/2 activity is necessary for CDCP1 protein
neo-synthesis, as demonstrated by the reduction of CDCP1 protein levels in presence of UO126, an inhibitor of ERK1/2
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various growth factors that we tested. As observed in a panel
of TNBC models, treatment with an ERK1/2 inhibitor under
standard culture conditions downregulated CDCP1, demon-
strating that this pathway is crucial for CDCP1 expression in
the TNBC phenotype. The MDA-MB-468 cell line was the
only model that showed no variation in the CDCP1 expres-
sion on ERK1/2 inhibition; similarly, it was the TNBC line
that upregulated CDCP1 RNA and protein the least on
treatment with WHD [3]. These data suggest the existence
of another regulatory mechanism in addition to RTK/ERK1/
2 activation. That ERK is less active when the PDGFRβ ex-
pression is abrogated in TNBC confirms the link between
these two tyrosine kinases. CDCP1 expression regulation,
upon PDGFRβ/ERK1/2 pathway activation, was investigated
also in non-breast cancer cells. CDCP1 expression did not
increase upon PDGF-BB treatment in the human large cell
lung cancer cells NCI-H460 (ATCC® HTB-177™), whereas it
was slightly up-regulated in the human esophageal adeno-
carcinoma cells OE19 (Sigma-Aldrich). Interestingly, in both
cell lines, the presence of ERK1/2 inhibitor strongly reduces
CDCP1 protein level (unpublished data). This data suggests
that ERK1/2 could be a crucial hub for the regulation of
CDCP1 expression, not only in breast cancer cells. As a sup-
port, it has been shown that CDCP1 expression is regulated
through ERK1/2 recruitment in ovarian cancer cells stimu-
lated with EGF [29]. On the contrary, the sensitivity to
PDGFRβ activation seems to be dependant by the cells.
The PDGFRβ axis is involved in breast cancer because
tumor tissue and the surrounding stroma express
PDGFRβ [33, 34]. Stromal PDGFRβ expression is associ-
ated with a poor prognosis [35, 36]. Also, breast cancer
cells and fibroblasts secreted PDGF-like factors that sus-
tain the PDGFR pathway in tumor cells [37, 38]. Consid-
ering the low expression of PDGFRα in MDA-MB-231
Table 1 Clinical characteristics of TNBC patients according to expression of PDGFRβ and CDCP1
Overall cohort
(N = 65b)
PDGFRβ pos
(N = 29b)
PDGFRβ neg
(N = 36b)
P valuec CDCP1 pos
(N = 37b)
CDCP1 neg
(N = 28b)
P valuec
Age
> = 50 years 42 (64.6%) 13 (44.8%) 29 (80.6%) 0,0040 22 (59.5%) 20 (71.4%) 0.4332
< 50 years 23 (35.4%) 16 (55.2%) 7 (19.4%) 15 (40.5%) 8 (28.6%)
Grade
I, II 9 (14.1%) 0 (0%) 9 (25.7%) 0,0029 5 (13.5%) 4 (14.8%) 1.0000
III 55 (85.9%) 29 (100.0%) 26 (74.3%) 32 (86.5%) 23 (85.2%)
na 1 1 1
Necrosis
No 14 (22.2%) 6 (20.7%) 8 (23.5%) 1,0000 6 (16.7%) 8 (29.6%) 0.2395
Yes 49 (77.8%) 23 (79.3%) 26 (76.5%) 30 (83.3%) 19 (70.4%)
na 2 2 1 1
Multifocality
No 52 (82.5%) 24 (82.8%) 28 (84.4%) 1,0000 28 (77.8%) 24 (88.9%) 0.3255
Yes 11 (17.5%) 5 (17.2%) 6 (17.6%) 8 (22.2%) 3 (11.1%)
na 2 2 1 1
N positivity
No 38 (58.5%) 17 (58.6%) 21 (58.3%) 1,0000 19 (51.4%) 19 (67.9%) 0.2117
Yes 27 (41.5%) 12 (41.4%) 15 (41.7%) 18 (48.6%) 9 (32.1%)
Size
> 2 cm 39 (60.9%) 11 (39.3%) 15 (41.7%) 0,8035 15 (40.5%) 10 (37.0%) 0.8015
< = 2 cm 25 (39.1%) 18 (64.3%) 21 (58.3%) 22 (59.5%) 17 (63.0%)
na 1 1 1
DCISa
No 40 (63.5%) 20 (68.9%) 20 (58.9%) 0,4424 23 (63.9%) 17 (63.0%) 1.0000
Yes 23 (36.5%) 9 (31.0%) 14 (41.2%) 13 (36.1%) 10 (37.0%)
na 2 2 1 1
aDCIS, ductal carcinoma in situ
bFrequency percentages were calculated on available cases
cFisher’s exact test
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cells [39], we cannot exclude that other isoforms of
PDGF receptors regulate CDCP1 expression. Notably, by
immunohistochemistry, PDGFRβ and CDCP1 expression
correlated significantly in a cohort of 65 TNBC speci-
mens, confirming that the PDGF-BB/PDGFRβ axis gov-
erns CDCP1 expression in human tumors.
However, supporting that several growth factor receptors
can regulate the expression of CDCP1, not all
CDCP1-positive specimens expressed PDGFRβ in the tumor
cells. We have reported that gains in CDCP1 are signifi-
cantly associated with CDCP1 expression but that nearly
half of CDCP1-positive cases do not show such gains. In the
Fig. 5 IHC staining of PDGFRβ and CDCP1 in TNBC. FFPE sections of TNBC specimens were analyzed by IHC for PDGFRβ and CDCP1.
a Representative image of a PDGFRβ- and CDCP1-positive case, with plasma membrane staining, at 10X and 40X magnification; b
Representative image of a PDGFRβ- and CDCP1-negative case, at 10X and 40X magnification
Table 2 PDGFRβ expression in tumor and vascular lacunae
according to expression of CDCP1 (IHC CDCP1)
IHC CDCP1 P valuea
Pos Neg
PDGFRβ tumor nest
Pos (N = 29) 21 (72.4%)b 8 (27.6%) 0.0429
Neg (N = 36) 16 (44.4%) 20 (55.5%)
PDGFRβ vascular lacunae
Pos (N = 27) 19 (70.4%) 8 (29.6%) 0.0795
Neg (N = 38) 18 (47.4%) 20 (52.6%)
aFisher’s exact test
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current study, in the absence of a gain in CDCP1, CDCP1
was expressed at the same frequency in PDGFRβ-positive
and -negative TNBC specimens, indicating that PDGFRβ
supports CDCP1 expression independently of a gain in
CDCP1. Accordingly, CDCP1 polysomy was observed in
MDA-MB-231 cells (data not shown), in which PDGFRβ
stimulation further increased basal CDCP1 levels.
Further, our group has demonstrated that the ability of
TNBCs to form vascular-like channels [28] is associated
with increased tumor aggressiveness and that this pheno-
type is related strictly to the expression of PDGFRβ [25].
Considering that CDCP1 also contributes to vasculogenic
mimicry [3], we hypothesize that PDGFRβ mediated this
peculiar TNBC phenotype by regulating the expression of
CDCP1. Accordingly, the association between PDGFRβ
and CDCP1 was nearly significant—almost 70% of vascular
lacunae that expressed PDGFRβ were positive for CDCP1.
In our previous paper on CDCP1 role in TNBC [3], we
showed that knock-down of CDCP1 expression in TNBC
cell lines did not affect their in vitro growth capability in
2D cultures and, accordingly, no association was found
between CDCP1 expression and proliferation rates in
TNBC specimens, evaluated by Ki-67 marker. Regarding
the role of PDGFRβ, it is crucial for the vasculogenic
properties of tumor cells, and therefore, its role in tumori-
genesis mainly accounts for the activation of migration/in-
vasion/angiogenesis pathways in cancer cells. Consistently,
in a previous paper [27], we reported that inhibition of
PDGFRβ pathways only slightly influences proliferation of
TNBC, and that its role in TNBC aggressiveness mainly
depends on the capacity to induce vasculogenic mimicry.
In conclusion, we have identified PDGF-BB/PDGFRβ as
a new pathway that is involved in the regulation of
CDCP1 expression in TNCBs through ERK1/2 activation.
Our results provide the basis for the potential use of
PDGFRβ and ERK1/2 inhibitors in targeting the high ag-
gressiveness of TNBCs.
Conclusions
We have identified PDGF-BB/PDGFRβ–mediated pathway
as a novel player in the regulation of CDCP1 in TNCBs
through ERK1/2 activation. Our results provide the basis
for the potential use of PDGFRβ and ERK1/2 inhibitors in
targeting the aggressive features of CDCP1-positive TNBCs.
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